This page lists the radiation oncology hospitals in our directory offering CAR T-Cell Therapy in Chennai, India, including Apollo Hospitals, Greams Road, Gleneagles Global Hospital, Dr. Rela Institute and Medical Centre, SIMS Hospital and others. Each listing links through to the hospital's full profile page.
Ask us about car t-cell therapy in Chennai, India
Share a few details and our care coordination team will get back to you with next steps.
Compare 8 accredited hospitals for Radiation Oncology in Chennai, India
Featured🇮🇳 Apollo Hospitals, Greams Road
Ranks #1 in this list by listed rating (4.7/5 from 125 reviews).
🇮🇳 Gleneagles Global Hospital
Ranks #2 in this list by listed rating (4.7/5 from 112 reviews).
🇮🇳 Dr. Rela Institute and Medical Centre
Ranks #3 in this list by listed rating (4.7/5 from 108 reviews).
🇮🇳 SIMS Hospital
Ranks #4 in this list by listed rating (4.6/5 from 20 reviews).
🇮🇳 Sankara Nethralaya
Ranks #5 in this list by listed rating (4.4/5 from 220 reviews).
🇮🇳 Apollo First Med Hospitals, Kilpauk
Ranks #6 in this list by listed rating (4.4/5 from 76 reviews).
🇮🇳 MIOT International
Ranks #7 in this list by listed rating (4.4/5 from 200 reviews).
🇮🇳 MGM Healthcare
Ranks #8 in this list by listed rating (3.7/5 from 34 reviews).
How we selected these hospitals
A hospital appears on this page when Radiation Oncology is among its listed specialties and it is located in Chennai, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How to Select the Best Hospital for CAR T-Cell Therapy in Chennai, India?
Choosing the right hospital for car t-cell therapy is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:
International Accreditation
Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.
Specialization
Check that the hospital's listed specialties actually include radiation oncology rather than only general care.
Capacity and Track Record
Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.
Transparent Costs
Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.
Understanding CAR T-Cell Therapy
CAR T-Cell Therapy (Chimeric Antigen Receptor T-Cell Therapy) is a groundbreaking, personalized immunotherapy that genetically engineers a patient's own T-lymphocytes to recognize and destroy cancer cells with precision unmatched by conventional chemotherapy or radiation. In landmark clinical trials, CAR T-Cell products such as axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah) have achieved complete remission rates of 40–54% in relapsed/refractory large B-cell lymphoma and up to 81% overall response rates in pediatric B-cell ALL. GAF Healthcare connects international patients with India's and the UAE's most advanced CAR T-Cell centers—offering JCI/NABH-accredited oncology programs, world-class apheresis infrastructure, and end-to-end logistics support at a fraction of Western costs. Hospital Stay: 21–35 days (inpatient monitoring phase: apheresis, conditioning chemotherapy, infusion, and acute toxicity management) • Total Stay in Country (Fit-to-Fly): 8–14 weeks (minimum 60–90 days post-infusion before international air travel is considered safe, subject to treating physician clearance, ECHO, and full blood count recovery) • Success Rate: 40–81% (varies by indication: ~81% ORR in pediatric B-ALL; 52–83% ORR in DLBCL; 65–85% in multiple myeloma with newer BCMA-targeted constructs)
Clinical Overview
CAR T-Cell Therapy represents a paradigm shift in the treatment of hematological malignancies and is increasingly being explored in solid tumors. The process begins with leukapheresis—collecting a patient's T-lymphocytes from peripheral blood—which are then sent to a Good Manufacturing Practice (GMP)-certified laboratory where they are retrovirally or lentivirally transduced to express a chimeric antigen receptor on their surface. This receptor is engineered to bind a specific tumor antigen (most commonly CD19 for B-cell malignancies, BCMA for multiple myeloma, or CD22 as an emerging target) with high affinity, bypassing the need for MHC-mediated antigen presentation that cancer cells frequently downregulate to evade immunity. Once the engineered cells have been expanded to therapeutic numbers (typically 10⁸–10⁹ cells over 2–4 weeks of manufacturing), the patient undergoes lymphodepletion chemotherapy—most commonly a fludarabine-cyclophosphamide regimen—to create immunological space that enhances CAR T-cell engraftment and persistence. The CAR T-cell product is then infused intravenously. The reinfused cells undergo robust in-vivo expansion, trafficking to tumor sites and initiating coordinated cytolytic activity. In responders, dramatic tumor regression can be observed within 1–4 weeks of infusion, and durable complete remissions lasting beyond 5 years have been documented in a subset of patients with diffuse large B-cell lymphoma (DLBCL) and B-cell ALL. The current standard of care for CAR T-Cell Therapy is governed by FDA/EMA approvals and NCCN guidelines, with six CAR T-cell products approved globally as of 2024: tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), lisocabtagene maraleucel (Breyanzi), brexucabtagene autoleucel (Tecartus), idecabtagene vicleucel (Abecma), and ciltacabtagene autoleucel (Carvykti). Hospitals in India and the UAE offering CAR T-Cell programs are equipped with certified GMP facilities, dedicated CAR T-Cell infusion units, 24/7 critical care for cytokine release syndrome (CRS) management, and neurology support for immune effector cell-associated neurotoxicity syndrome (ICANS).
Who is a Candidate?
• ELIGIBLE DIAGNOSES: Relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after ≥2 prior lines of systemic therapy; R/R follicular lymphoma (grade 3B); R/R mantle cell lymphoma; R/R B-cell acute lymphoblastic leukemia (B-ALL) in pediatric and young adult patients (up to age 25); R/R multiple myeloma after ≥4 prior lines (including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 antibody). • PERFORMANCE STATUS: ECOG performance status 0–2; Karnofsky Performance Score ≥60%. • ORGAN FUNCTION REQUIREMENTS (ELIGIBILITY THRESHOLD): Creatinine clearance ≥45 mL/min (CKD-EPI formula); ALT/AST ≤5× ULN; total bilirubin ≤2× ULN; LVEF ≥50% confirmed on 2D Echocardiography (ECHO) or MUGA scan; no active Grade ≥3 pulmonary dysfunction (baseline O₂ saturation ≥92% on room air). • REQUIRED DIAGNOSTIC WORKUP BEFORE TRAVEL: Whole-body PET-CT scan (FDG) within 4 weeks; bilateral bone marrow biopsy with flow cytometry and cytogenetics; complete blood count with differential and comprehensive metabolic panel; serum protein electrophoresis and immunofixation (for myeloma); HLA typing (for allogeneic considerations); infectious disease panel (HIV Ag/Ab, Hepatitis B surface Ag and core Ab, Hepatitis C Ab, CMV IgG/IgM, EBV VCA IgG, quantitative CMV PCR); cardiac ECHO; pulmonary function tests (FEV1, DLCO); MRI brain (to rule out CNS disease or ICANS risk factors); prior treatment records including all chemotherapy regimens, radiation fields, stem cell transplant history. • RELATIVE CONTRAINDICATIONS: Active, uncontrolled infection including active Hepatitis B replication (HBV DNA detectable); active CNS malignancy with mass lesion >1 cm (relative, not absolute); history of severe autoimmune disease requiring systemic immunosuppression; prior allogeneic HSCT within 6 months or active graft-versus-host disease (GVHD) on immunosuppression; active corticosteroid use (>10 mg prednisone/day equivalent) within 72 hours of infusion; pregnancy or lactation. • ABSOLUTE CONTRAINDICATIONS: Prior CAR T-cell therapy targeting the same antigen with disease progression attributable to antigen loss; severe irreversible cardiac failure (LVEF <35%); uncontrolled grade 4 pulmonary dysfunction.
Treatment Options & Approaches
CAR T-Cell Therapy is not a single procedure but a multi-step biological manufacturing and clinical delivery process. The following approaches and product categories are available at partner centers in India and the UAE: 1. AUTOLOGOUS CAR T-CELL THERAPY (CURRENT STANDARD): The patient's own T-cells are harvested, engineered, and reinfused. Products include FDA/EMA-approved tisagenlecleucel (lentiviral CD19-targeting), axicabtagene ciloleucel (retroviral, CD19), lisocabtagene maraleucel (lentiviral, CD19, defined 4-1BB co-stimulatory domain with a 1:1 CD4:CD8 ratio for reduced neurotoxicity risk), brexucabtagene autoleucel (retroviral, CD19, specifically approved for mantle cell lymphoma), and BCMA-targeting constructs idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma. Manufacturing turnaround time ranges from 17 to 22 days for most commercial products. 2. LOCALLY MANUFACTURED / ACADEMIC CAR T-CELL PROGRAMS (INDIA-SPECIFIC): Several institutions in India—including Tata Memorial Centre (Mumbai), AIIMS (New Delhi), and Christian Medical College (Vellore)—have established indigenous CAR T-Cell manufacturing programs under the Central Drugs Standard Control Organisation (CDSCO) regulatory framework. India's first indigenously developed CD19 CAR T-Cell product (developed collaboratively by ACTREC and IIT Bombay) received CDSCO approval in 2023, at a significantly reduced cost compared to imported commercial products ($40,000–$70,000 vs. $350,000+ in Western markets). This is a critical cost advantage for international patients. 3. DUAL-ANTIGEN / BISPECIFIC CAR T-CELL CONSTRUCTS (INVESTIGATIONAL / CLINICAL TRIALS): Available at select academic centers; constructs targeting CD19/CD22 simultaneously are designed to overcome antigen escape—a primary mechanism of relapse after single-antigen CD19 CAR T-Cell therapy. Patients who have failed prior CD19 CAR T-Cell treatment may be eligible. 4. ALLOGENEIC (OFF-THE-SHELF) CAR T-CELL THERAPY: Using donor-derived T-cells (allogeneic) with additional gene edits to reduce graft-versus-host potential. Still predominantly investigational (Phase I/II trials); available at select centers in the UAE (e.g., Cleveland Clinic Abu Dhabi's oncology program). Offers faster availability without the manufacturing delay inherent to autologous collection. 5. LYMPHODEPLETION REGIMEN SELECTION: The standard fludarabine (30 mg/m² × 3 days) + cyclophosphamide (500 mg/m² × 3 days) regimen is used most commonly. Bendamustine-based lymphodepletion is an alternative for patients with fludarabine intolerance (e.g., significant renal impairment). The conditioning regimen profoundly influences CAR T-cell expansion kinetics and clinical response. 6. TOXICITY MANAGEMENT TECHNOLOGIES: All partner centers utilize the ASTCT 2019 CRS and ICANS grading consensus criteria. Management protocols include tocilizumab (anti-IL-6R) as first-line CRS intervention, corticosteroids for Grade ≥2 ICANS, and siltuximab as a second-line agent. Continuous EEG monitoring is available for high-risk ICANS patients. Ferritin, IL-6, CRP, and D-dimer are monitored daily during the acute post-infusion phase as biomarkers of CRS severity and hemophagocytic lymphohistiocytosis (HLH) risk.
Recovery
PHASE 1 — PRE-TRAVEL CONSULTATION (2–4 weeks before departure): • Upload complete medical records, PET-CT, bone marrow biopsy, and prior treatment summaries to GAF Healthcare's secure patient portal. • GAF's oncology case managers facilitate a teleconsultation with the destination center's CAR T-Cell specialist within 48–72 hours. • Treatment eligibility is confirmed; manufacturing slot is reserved with the CAR T-Cell program. • India: e-Medical Visa (e-MV) application assisted by GAF (processing 3–5 business days). UAE: Visa-on-arrival or visa waiver available for 50+ nationalities; GAF assists with medical invitation letter for others. PHASE 2 — ARRIVAL & PRE-TREATMENT WORKUP (Days 1–5 in country): • Airport-to-hospital transfer via GAF's dedicated medical transport. • Comprehensive baseline evaluation: repeat PET-CT (if >4 weeks since last scan), ECHO, pulmonary function tests, CNS MRI, infectious disease re-screening, and a multidisciplinary team (MDT) review involving hematological oncology, critical care, neurology, and pharmacy. • Bridging chemotherapy may be administered during this phase if disease is rapidly progressing or if manufacturing time exceeds 3 weeks. PHASE 3 — LEUKAPHERESIS (Day 5–7): • Outpatient or inpatient apheresis procedure (3–5 hours) via a large-bore peripheral IV or apheresis catheter. T-lymphocytes are collected and cryopreserved. • Product is shipped under controlled cryogenic conditions (-196°C liquid nitrogen) to the GMP manufacturing facility (domestic or international, depending on the product selected). • Patient may return to GAF-arranged accommodation or remain hospitalized for bridging therapy during the manufacturing period (17–22 days for commercial products; 4–6 weeks for some academic products). PHASE 4 — BRIDGING THERAPY & MONITORING (Days 7–28 approximately): • Low-intensity bridging chemotherapy (e.g., polatuzumab vedotin-based, bendamustine-rituximab, or steroid-based regimens) to control disease burden without compromising T-cell collection viability. • Serial CBC monitoring and clinical assessment. • Patient and one designated caregiver/attendant are housed in GAF-arranged serviced apartments or hospital guest houses within 15 minutes of the treatment center. PHASE 5 — LYMPHODEPLETION CHEMOTHERAPY (Days -5 to -1 relative to infusion): • Hospital admission. • Fludarabine + cyclophosphamide administered intravenously over 3 consecutive days. • Anti-emesis, hydration, and mesna uroprotection protocols initiated. • Baseline cytokine panel drawn (IL-6, ferritin, fibrinogen, CRP, LDH). PHASE 6 — CAR T-CELL INFUSION (Day 0): • Cryopreserved CAR T-cell product is thawed and administered intravenously in the dedicated CAR T infusion suite (HEPA-filtered positive or negative pressure room depending on protocol). • Infusion duration: 15–60 minutes depending on product and volume. • Vitals, oxygen saturation, and neurological status monitored continuously for 2 hours post-infusion, then every 4 hours for 48 hours. PHASE 7 — ACUTE MONITORING (Days 1–14 post-infusion, mandatory inpatient): • CRS onset typically Day 1–7: fever, hypotension, hypoxia managed with tocilizumab ±corticosteroids per institutional protocol. • ICANS onset typically Day 5–10: neurocognitive assessment using CARTOX-10 score or ICE score twice daily; EEG if score drops ≤7. • Daily labs: CBC, CMP, LFTs, coagulation panel, ferritin, IL-6, CRP, fibrinogen, D-dimer, and quantitative CAR T-cell expansion by peripheral blood flow cytometry or qPCR. • MILESTONE: Safe hospital discharge typically occurs Day 10–21 if CRS resolves to Grade ≤1 and ICANS resolves to Grade ≤1. PHASE 8 — OUTPATIENT RECOVERY (Days 15–60 post-infusion): • Mandatory outpatient clinic visits: twice weekly for the first 4 weeks, then weekly through Day 60. • Monitoring for late CRS, prolonged cytopenia (B-cell aplasia, neutropenia), hypogammaglobulinemia (requiring IVIG supplementation), and secondary HLH. • Infectious prophylaxis: acyclovir (HSV/VZV), fluconazole or posaconazole (fungal), and PCP prophylaxis (trimethoprim-sulfamethoxazole or pentamidine). • CAR T-cell persistence measured at Day 28, Day 60, and Day 90. PHASE 9 — RESPONSE ASSESSMENT & FIT-TO-FLY CLEARANCE (Week 8–14): • PET-CT response assessment at Day 28–30 and Day 90 per Lugano 2014 criteria. • Treating physician issues fit-to-fly certificate when: ANC >1,000/μL sustained, platelet count >50,000/μL, no active CRS/ICANS, no supplemental oxygen requirement, and ECHO confirms preserved LVEF. • Most patients are cleared for international travel between 8 and 14 weeks post-infusion; some with protracted cytopenias or hypogammaglobulinemia may require 16 weeks. • GAF Healthcare coordinates the discharge summary, digital medical records transfer, and teleconsultation scheduling with the patient's home oncologist.
Risks to be aware of
CAR T-Cell Therapy carries a distinct and serious toxicity profile that patients and caregivers must understand thoroughly before initiating treatment. Cytokine Release Syndrome (CRS) is the most common acute toxicity, occurring in 57–93% of patients depending on the product and disease burden; Grade 3–4 CRS (severe hypotension, Grade 3+ hypoxia requiring high-flow oxygen or mechanical ventilation) occurs in 13–22% of cases and requires ICU-level management including vasopressors and tocilizumab. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) occurs in 20–60% of patients, presenting as confusion, aphasia, tremor, and in severe cases (Grade 4), seizures, cerebral edema, and rarely death; the mortality risk from Grade 4 ICANS is approximately 1–3%. Prolonged and severe cytopenias (neutropenia, anemia, thrombocytopenia) lasting beyond 30 days occur in 30–40% of patients and substantially increase infection risk; febrile neutropenia requires prompt hospitalization and broad-spectrum antibiotics. B-cell aplasia is an expected on-target off-tumor effect of CD19 CAR T-Cell products and leads to hypogammaglobulinemia requiring monthly IVIG infusions, sometimes for 12–24 months post-treatment. Hemophagocytic lymphohistiocytosis (HLH) is a rare (2–5%) but life-threatening hyperinflammatory complication associated with a mortality rate of 30–50% if not recognized promptly; it is characterized by hyperferritinemia (>10,000 ng/mL), cytopenias, and liver dysfunction. Tumor lysis syndrome (TLS) can occur in the context of rapid disease response, particularly in high-burden lymphoma, and requires aggressive pre-infusion hydration and urate-lowering therapy (allopurinol or rasburicase). Late-onset infections—particularly with encapsulated bacteria, CMV reactivation, and opportunistic fungi—remain a risk during the 6–12 months of immune reconstitution. Disease relapse, occurring in 30–60% of responders within 2 years, may be mediated by antigen loss (CD19 downregulation), T-cell exhaustion, or immunosuppressive tumor microenvironment, and may require subsequent therapy. All patients must have a dedicated caregiver present 24 hours per day during the mandatory inpatient and early outpatient phases. Travel insurance must specifically cover CAR T-Cell-related complications; GAF Healthcare's partner insurance advisors assist with policy identification.
Why GAF Healthcare
GAF Healthcare provides a fully integrated, end-to-end logistics infrastructure designed specifically for the complexity of CAR T-Cell therapy, where timing, proximity to the treatment center, and rapid access to emergency care during the post-infusion monitoring period are non-negotiable. VISA ASSISTANCE — INDIA: GAF Healthcare's visa coordination team assists patients with the Indian e-Medical Visa (e-MV) application, which permits a stay of up to 60 days per entry (extendable to 180 days for treatment requiring prolonged stay). The e-MV is typically processed within 3–5 business days upon submission of a medical invitation letter from the treating hospital—which GAF secures on the patient's behalf. One accompanying attendant is eligible for an e-Medical Attendant Visa simultaneously. VISA ASSISTANCE — UAE: Citizens of 50+ countries benefit from visa-on-arrival (30–90 days) or visa-free entry to the UAE. Nationals of countries requiring advance visas are supported with GAF's medical visit visa application service, including a formal invitation letter from the UAE-accredited hospital and medical documentation packet. AIRPORT & INTER-CITY TRANSFERS: GAF arranges compliant medical transport from the airport to the treatment center—standard saloon vehicles for ambulatory patients and fully equipped medical transport vans (with stretcher capability and an attending nurse) for patients with compromised ECOG status. All transfers in India and the UAE are coordinated in real time and scheduled around flight arrivals to minimize patient fatigue. ACCOMMODATION FOR PATIENT AND ATTENDANT: Given the 8–14-week required stay, GAF Healthcare negotiates extended-stay serviced apartment packages located within a 10–15-minute drive of partner hospitals in Mumbai, New Delhi, Chennai, Hyderabad (India), and Dubai, Abu Dhabi (UAE). Accommodation includes hospital-grade hygiene protocols (HEPA air filtration available on request for immunocompromised patients), laundry, daily housekeeping, and 24-hour security. Costs range from $40–$90 per night in India and $100–$200 per night in the UAE, significantly below comparable hotel rates. DEDICATED CASE MANAGER & TRANSLATORS: Each patient is assigned a dedicated GAF Healthcare case manager who serves as a single point of contact from initial inquiry through post-discharge. The case manager coordinates appointment scheduling, lab result communication, pharmacy procurement, and emergency escalation. Language interpretation services are available in Arabic, Russian, French, Swahili, Uzbek, Kazakh, and 12 other languages—provided either in-person at the hospital or via a certified medical interpreter on video call for consultations. REMOTE MONITORING SUPPORT & TELECONSULTATION: After returning home, GAF Healthcare facilitates structured teleconsultation follow-ups at Day 90, Day 180, and Month 12 with the treating CAR T-Cell oncologist. Lab results from the patient's local facility can be uploaded to the GAF digital health portal and reviewed remotely. Emergency escalation protocols are in place 24/7 for patients who develop late-onset CRS, ICANS, or infection within 6 months of returning home.
Common questions about CAR T-Cell Therapy
What is the cost of CAR T-Cell Therapy in India vs the UAE?
How long do I need to stay in the country before I am fit to fly home after CAR T-Cell Therapy?
What is the success rate of CAR T-Cell Therapy?
Related pages
How GAF Healthcare Assists in Choosing the Best Hospital for CAR T-Cell Therapy in Chennai, India
Discover the Top Hospitals for CAR T-Cell Therapy in Chennai, India
This page lists 8 accredited radiation oncology hospitals in Chennai, India, so you can compare accreditation, specialties and bed capacity in one place.
Support When You Need It Most
Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.
Transparent, All-Inclusive Costs
We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.
Visa, Travel and Stay Coordination
Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.
Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.
Frequently asked questions about car t-cell therapy in Chennai, India
How many radiation oncology hospitals are listed in Chennai, India?
How do you choose which hospitals to list?
How much does treatment cost in India?
Are there radiation oncology hospitals for this in other India cities?
Next Step
Share your medical reports with us and our team will recommend a hospital and treatment plan for car t-cell therapy in Chennai, India.
Contact us to report an inaccuracy on this page.